Eagle, Eli Lilly Drop Dueling Cancer Drug Patent Claims
By Matthew Perlman ( December 17, 2019, 4:37 PM EST) -- Eagle Pharmaceuticals has agreed to drop its lingering antitrust claims over Eli Lilly's chemotherapy drug Alimta after the companies reached a settlement ending patent litigation and allowing Eagle to launch a branded alternative in 2022....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.